TRAF6 and breast carcinoma: In turn, TRAF-6/TAK-1 joins the MAPK pathway and upregulates the subsequent phosphorylation of extracellular signal-regulated kinases (ERK1/2) in all human breast cancer, thus leading to uncontrolled growth, proliferation, and resistance to traditional chemotherapeutic agents such as docetaxel (26).